Thomas Cannell, Sesen Bio CEO
January 20, 2023 10:36 AM EST
Financing
Deals

Sesen takes next step af­ter in­vestor at­tack, calls for share­hold­er vote to ap­prove merg­er

Paul Schloesser

Associate Editor

Two and a half weeks af­ter Sesen Bio pushed back against an in­vestor group op­pos­ing a merg­er with Caris­ma Ther­a­peu­tics, the biotech is mov­ing for­ward …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times